ReviewAmerican journal of cancer research2021
Management of hepatotoxicity of chemotherapy and targeted agents.
Review in American journal of cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Trial
- Diagnostic BMI and Induction Therapy Weight Change Associated With Hepatotoxicity in Pediatric Patients With Acute Lymphoblastic Leukemia.Cancer medicine · 2026Article
- Emerging Role of Ferroptosis in Chemotherapy-Associated Hepatorenal Toxicity: Mechanistic Insights and Toxicological Perspectives.ACS pharmacology & translational science · 2026Review
- Article
- The Therapeutic Potential of Stem Cell Therapy for Doxorubicin-Induced Cardiotoxicity: A Narrative Review.Health science reports · 2026Article
- Ethnic Differences in the Association Between SOD2 rs4880 and Hepatotoxicity in Pediatric Acute Lymphoblastic Leukemia: A Report From the REDIAL Consortium.Pediatric blood & cancer · 2026Article
- Postoperative complications in patients with chemotherapy-induced acute myeloid leukemia (Review).Oncology letters · 2026Review
- Lipidomic profiles associated with treatment related hepatotoxicity in children with acute lymphoblastic leukemia.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Myricetin protects against doxorubicin-induced liver damage by modulating oxidative and inflammatory pathways.BMC pharmacology & toxicology · 2026Article
- Trends in liver failure-related mortality among middle-aged and older adults with digestive system malignant tumors in the United States, 1999-2023.Frontiers in oncology · 2026Article
- Incidence and Risk Factors of Chemotherapy-Induced Hepatotoxicity: A Cross-Sectional Study.Cancer management and research · 2026Article
- Article
- Risk factors for irinotecan-induced hepatotoxicity: a retrospective cohort study.Frontiers in oncology · 2026Article
- Successful management of severe hepatotoxicity induced by combined chemotherapy and immune checkpoint inhibitor: a case report.Frontiers in medicine · 2026Article
- Chronic liver disease and cirrhosis mortality following surgery for colon or rectal cancer.Scientific reports · 2025Article
- SoloxoloneInternational journal of molecular sciences · 2025Article
- Evaluation of Inflammatory Biomarkers Gal-1 and IL-1β and Liver Enzyme Activities in Gastric Cancer Patients Pre- and Post-Chemotherapy: A Case-Control Study.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Association Between Dietary Vitamin K Intake With Cancer Cachexia and Mortality: NHANES 1999-2018.Food science & nutrition · 2025Article
- Comprehensive Evaluation of Hepatotoxicity Following Radiation Therapy in Breast Cancer Patients.Cancers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatotoxicity of chemotherapeutic agents such as methotrexate, oxaliplatin, and irinotecan have been well documented and characterized allowing for careful management by oncologists during administration. However, the rapid advance of the field of oncology and introduction of new classes of therapies such as small molecule inhibitors and immunotherapies have introduced new hepatotoxicity challenges and management strategies. This work is a compilation of the hepatotoxicity and recommended management of various chemotherapies and targeted agents, with a focus on the newer classes of targeted anticancer agents.
Indexed as
Identifiers
34354855PMC8332851What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.